Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL663212 | 0.74 | MAPT (0.40) | MAPTMEN1KMT2A | |
| SCHEMBL9389321 | 0.71 | MAPT (0.38) | MAPT | |
| SCHEMBL10740451 | 0.70 | MEN1 (0.52) | MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL6080759 | 0.70 | AURKA (0.47) | MAPTSMN1; SMN2MEN1KMT2ACHRNB2 | |
| SCHEMBL5638554 | 0.69 | SMN1; SMN2 (0.44) | MAPTSMN1; SMN2MEN1KMT2ACHRNB2 | |
| SCHEMBL334795 | 0.69 | MAPT (0.44) | MAPTMEN1KMT2A | |
| SCHEMBL223705 | 0.69 | MAPT (0.44) | MAPT | |
| SCHEMBL6560556 | 0.68 | LMNA (0.42) | MAPTMEN1KMT2A | |
| SCHEMBL7778414 | 0.67 | MAPT (0.42) | MAPT | |
| SCHEMBL10802916 | 0.67 | MAPT (0.42) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079503-A1 | Thiazolidinones and the use therof as polo-like kinase inhibitors | SCHERING AKTIENGESELLSCHAFT | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079503-A1 | Thiazolidinones and the use therof as polo-like kinase inhibitors | PLK4, PLK2, PLK3 | MAPT 1138/4885POLB 140/4885SMN1; SMN2 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.